MSLE Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company us…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application Satellos Bioscience (MSCL.TO) said on Thursday that the US Food and Drug Administration (FDA) has cl | ||
 Satellos Receives FDA Clearance to Study Forazapadin in FSHD Satellos Bioscience Inc. (NASDAQ:MSLE) has received clearance from the U. | ||
Satellos stock jumps after FDA clears FSHD trial for forazapadin Investing.com -- Satellos Bioscience Inc (NASDAQ:MSLE) shares rose 6.8% in premarket trading Thursday after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). | ||
 Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants. The company reported results from four ad | ||
 Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD) The data showed that SAT-3247-treated DMD patients experienced improvements in muscle composition and upper limb activity while maintaining stable strength. The company also said the drug continued to demonstrate a favorable safety and tolerability profile, supporting its continued clinical development. Read Also: | ||
Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients Satellos Bioscience (MSLE) said Wednesday six-month interim data from a phase 2 trial showed that it | ||